AMD in action : CDC scientists use AMD methods to develop diagnostic tools for Zika virus by unknown
AMD in Action 
CDC’s Advanced Molecular Detection (AMD) initiative fosters scientific innovation in genomic sequencing,  
epidemiology, and bioinformatics to transform public health and protect people from disease threats. 
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CDC scientists used AMD to sequence the 
genomes of several Zika strains and rapidly 
develop, validate, and distribute a molecular 
diagnostic assay protocol to detect emerging 
strains of the virus. 
Almost directly on the heels of the chikungunya virus, the 
Western Hemisphere faces a new mosquito-borne threat – 
Zika Virus. And this virus appears to bring tragic consequences 
for some babies – microcephaly, a devastating birth defect in 
which a baby’s head is smaller than expected. 
In May 2015, the Pan American Health Organization (PAHO) 
issued an alert regarding the first confirmed Zika virus infection 
in Brazil. Later that year, Brazilian clinicians saw an increase in 
babies born with microcephaly. There is evidence that at least 
some babies born with microcephaly were infected with Zika 
virus. This development prompted CDC to issue travel notices 
and interim recommendations for women who were pregnant 
or thinking of becoming pregnant and traveling from the 
United States to countries in South and Central America. 
During the Zika outbreak in Brazil, CDC scientists in the Division 
of Vector-Borne Diseases used advanced molecular 
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For more information on this new mosquito-borne threat, please visit the CDC website on Zika Virus (www.cdc.gov/
zika/index.html) and microcephaly (www.cdc.gov/ncbddd/birthdefects/microcephaly.html). 
 
detection (AMD) to sequence the genomes of several of these Western Hemisphere viruses. Studying the 
genome of Zika strains helped scientists map the spread of the virus, which appears to  
have come from the Asian-Pacific region, where outbreaks occurred previously. CDC shared the 
genomic sequence data in public databases so other researchers can access them. 
CDC scientists also used these genomic data to rapidly develop a molecular diagnostic assay protocol to 
detect emerging Zika virus strains. Building on experience applying AMD technology to address the 
emergence of chikungunya virus, they were able to develop, validate, and distribute this assay protocol 
for use in laboratories throughout the Western Hemisphere within three weeks of having received the first 
Zika virus-positive sample. With older methods, this would have required 3‒4 months. PAHO flew CDC 
scientists to South America to train laboratory scientists from Brazil and other Latin American countries on 
how to perform the diagnostic test. 
As of early February 2016, investigators have confirmed Zika virus in babies born in Brazil with microcephaly 
and poor pregnancy outcomes. Scientists are working to better characterize this relationship. Specifically, 
they want to determine what role the virus plays in microcephaly and whether additional factors (such as 
nutrition or exposure to other microorganisms) contribute to birth defects and other poor pregnancy 
outcomes. CDC will continue to use AMD methods to study Zika and its possible links to health outcomes. 
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